• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: C.R. BARD, INC. (GFO) LUTONIX 035 DRUG COATED BALLOON PTA CATHETER

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

C.R. BARD, INC. (GFO) LUTONIX 035 DRUG COATED BALLOON PTA CATHETER Back to Search Results
Model Number 9004
Medical Device Problem Code Adverse Event Without Identified Device or Use Problem (2993)
Health Effect - Clinical Code Reocclusion (1985)
Date of Event 12/02/2016
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
Analysis: the sample was not returned from the user facility; therefore, a device evaluation is unable to be performed.A lot history review revealed 3 additional reocclusion complaints were associated with this lot.A review of the device history record (dhr) indicates the lot was manufactured to specification.Conclusion: the actual sample was not received for evaluation.The dhr found nothing to indicate a manufacturing related cause for this event.The investigator assessed the event was not related to the study device or procedure.Based on the instructions for use (ifu), the occurrence of reocclusion is an inherent risk of any pta procedure, and has been reported in clinical trials of drug coated balloons.If additional information becomes known to the manufacturer, a supplemental report will be provided will all relevant information.The information provided by bard represents all of the known information at this time.Despite good faith efforts to obtain additional information, the complainant / reporter was unable or unwilling to provide any further patient, product, or procedural details to bard.
 
Event or Problem Description
It was reported through a clinical registry that during the index procedure, a lutonix percutaneous transluminal drug coated balloon (dcb) dilatation catheter was used to treat the target lesion located in the left superficial femoral artery (sfa).Approximately 11 months after the index procedure, the patient¿s left sfa vasculature was reportedly reoccluded.A revascularization was performed and the hcp deemed it was successful.The investigator assessed that the event was not related to the study device or procedure.The sample was discarded by the user facility and is not available for evaluation.No adverse patient effects were reported.
 
Event or Problem Description
It was reported through a clinical registry that during the index procedure, a lutonix percutaneous transluminal drug coated balloon (dcb) dilatation catheter was used to treat the target lesion located in the left popliteal artery.Approximately 5 months after the index procedure, the patient¿s left popliteal vasculature was reportedly reoccluded.A revascularization was performed and the hcp deemed it was successful.The investigator assessed that the event was not related to the study device or procedure.The sample was discarded by the user facility and is not available for evaluation.No adverse patient effects were reported.
 
Additional Manufacturer Narrative
Additional information: the patient's weight was added with measurement units, (b)(6).The other relevant history had the patient's medical history added "past medical history includes: hypertension, dyslipidemia, former smoker, coronary artery disease (cad), myocardial infarction in 1999, valvular heart disease, aortic valve regurgitation in 2012, mitral valve regurgitation in 2012, tricuspid valve regurgitation in 2012, left ventricular dysfunction, peripheral artery disease (pad) in 2015, stage 3 chronic kidney disease (ckd), rutherford class unknown in left leg." also, the following statement "patient weight is unavailable" was taken out because this information was obtained.Corrected data: the event description was changed from " it was reported through a clinical registry that during the index procedure, a lutonix percutaneous transluminal drug coated balloon (dcb) dilatation catheter was used to treat the target lesion located in the left superficial femoral artery (sfa).Approximately 11 months after the index procedure, the patient¿s left sfa vasculature was reportedly reoccluded.A revascularization was performed and the hcp deemed it was successful.The investigator assessed that the event was not related to the study device or procedure.The sample was discarded by the user facility and is not available for evaluation.No adverse patient effects were reported" to "it was reported through a clinical registry that during the index procedure, a lutonix percutaneous transluminal drug coated balloon (dcb) dilatation catheter was used to treat the target lesion located in the left popliteal artery.Approximately 5 months after the index procedure, the patient¿s left popliteal vasculature was reportedly reoccluded.A revascularization was performed and the hcp deemed it was successful.The investigator assessed that the event was not related to the study device or procedure.The sample was discarded by the user facility and is not available for evaluation.No adverse patient effects were reported." analysis: the sample was not returned from the user facility; therefore, a device evaluation is unable to be performed.A lot history review revealed 3 additional reocclusion complaints were associated with this lot.A review of the device history record (dhr) indicates the lot was manufactured to specification.Conclusion: the actual sample was not received for evaluation.The dhr found nothing to indicate a manufacturing related cause for this event.The investigator assessed the event was not related to the study device or procedure.Based on the instructions for use (ifu), the occurrence of reocclusion is an inherent risk of any pta procedure, and has been reported in clinical trials of drug coated balloons.If additional information becomes known to the manufacturer, a supplemental report will be provided will all relevant information.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
LUTONIX 035 DRUG COATED BALLOON PTA CATHETER
Common Device Name
DRUG COATED BALLOON PTA CATHETER
Manufacturer (Section D)
C.R. BARD, INC. (GFO)
289 bay road
queensbury NY 12804
MDR Report Key6980993
Report Number3006513822-2017-00217
Device Sequence Number1824680
Product Code ONU
UDI-Device Identifier00801741088605
UDI-Public(01)00801741088605
Combination Product (Y/N)N
Initial Reporter StateWI
Initial Reporter CountryUS
PMA/510(K) Number
P130024
Number of Events Summarized1
Summary Report (Y/N)N
Reporter Type Manufacturer
Report Source health professional,other,stu
Initial Reporter Occupation Physician
Type of Report Initial,Followup
Report Date (Section B) 03/15/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Expiration Date09/22/2017
Device Model Number9004
Device Catalogue NumberLX35130660
Device Lot NumberGFZI2849
Was Device Available for Evaluation? No
Event Location Hospital
Initial Date Received by Manufacturer Not provided
Supplement Date Received by Manufacturer02/27/2018
Initial Report FDA Received Date10/26/2017
Supplement Report FDA Received Date03/15/2018
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Patient Sequence Number1
Outcome Attributed to Adverse Event Required Intervention;
Patient Age73 YR
Patient Weight59
-
-